SEOUL, Korea & FAIR LAWN, N.J.--(BUSINESS WIRE)--SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811. The goal of this program is to develop a drug with once-a-day oral dosing and improved efficacy and safety for the treatment of chronic constipation and other disorders related to reduced gastrointestinal (GI) motility. Recently, SK Biopharmaceuticals successfully completed their Phase 1 trials in the US.
